Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single‐blind, placebo‐controlled study, following once‐daily multiple ascending dosing to steady‐state in healthy subjects. Target engagement was...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelander, Karin, Lagerstrom‐Fermer, Maria, Amilon, Carl, Michaëlsson, Erik, Heijer, Maria, Kjaer, Magnus, Russell, Muir, Han, David, Lindstedt, Eva‐Lotte, Whatling, Carl, Gan, Li‐Ming, Ericsson, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212712/
https://www.ncbi.nlm.nih.gov/pubmed/32770730
http://dx.doi.org/10.1111/cts.12859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212712/
https://www.ncbi.nlm.nih.gov/pubmed/32770730
http://dx.doi.org/10.1111/cts.12859

Ejemplares similares